Eisenberg P R, Sobel B E, Jaffe A S
Cardiovascular Division, Washington University School of Medicine, Saint Louis, Missouri.
J Am Coll Cardiol. 1992 Apr;19(5):1065-9. doi: 10.1016/0735-1097(92)90296-y.
Increases in thrombin activity in patients given fibrinolytic agents for acute myocardial infarction have been shown to be important in limiting the ultimate success of coronary thrombolysis. The present study was designed to determine whether increases in thrombin activity reflect, in part, activation of prothrombin accompanying thrombolysis. Plasma concentrations of prothrombin fragment 1.2, a polypeptide released when prothrombin is activated by factor Xa, were measured in 22 patients with acute myocardial infarction before and after treatment with 100 mg of recombinant tissue-type plasminogen activator (rt-PA). Concentrations of prothrombin fragment 1.2 increased from 0.83 +/- 1.1 nM (mean +/- SD) before rt-PA infusion to 1.5 +/- 1.5 nM 2 h after initiation of the infusion (p less than 0.05). After a 5,000-U intravenous dose of heparin given at the end of the infusion of rt-PA, concentrations of prothrombin fragment 1.2 decreased from 1.8 +/- 1.5 to 1.1 +/- 0.9 nM (n = 20, p less than 0.05), although values were still increased compared with concentrations before rt-PA. These results indicate that thrombin activity increases in patients given rt-PA at least in part because of activation of the coagulation system leading to activation of prothrombin. Thus, inhibition of the reactions involving coagulant proteins that lead to activation of prothrombin may be of value as conjunctive treatment to potentiate the efficacy of pharmacologic thrombolysis.
在接受纤维蛋白溶解剂治疗急性心肌梗死的患者中,凝血酶活性的增加已被证明在限制冠状动脉溶栓的最终成功方面起着重要作用。本研究旨在确定凝血酶活性的增加是否部分反映了溶栓过程中凝血酶原的激活。在22例急性心肌梗死患者中,在给予100mg重组组织型纤溶酶原激活剂(rt-PA)治疗前后,测定了凝血酶原片段1.2的血浆浓度,凝血酶原片段1.2是凝血酶原被因子Xa激活时释放的一种多肽。凝血酶原片段1.2的浓度从rt-PA输注前的0.83±1.1nM(平均值±标准差)增加到输注开始后2小时的1.5±1.5nM(p<0.05)。在rt-PA输注结束时静脉注射5000U肝素后,凝血酶原片段1.2的浓度从1.8±1.5降至1.1±0.9nM(n = 20,p<0.05),尽管与rt-PA治疗前的浓度相比仍有所升高。这些结果表明,接受rt-PA治疗的患者凝血酶活性增加至少部分是由于凝血系统激活导致凝血酶原激活。因此,抑制导致凝血酶原激活的涉及凝血蛋白的反应,作为联合治疗以增强药物溶栓的疗效可能具有价值。